Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality

Noemi Pavo,1 Markus Raderer,2 Martin Hülsmann,1 Stephanie Neuhold,3 Christopher Adlibrecht,1 Guido Strunk,4 Georg Goliash,1 Heinz Gisslinger,2 Günther G Steger,2 Michael Hejna,2 Wolfgang Köstler,2 Sabine Zöchbauer-Müller,2 Christine Marosi,2 Gabriela Kornek,2 Leo Auerbach,5 Sven Schneider,6 Bernhard Parshalk,5 Werner Scheithauer,2 Robert Pirker,2 Johannes Drach,2 Christoph Zielinski,2 Richard Pacher1

ABSTRACT
Objective Patients with cancer may display elevated levels of B-type natriuretic peptide (BNP) and high-sensitive troponin T (hsTnT) without clinical manifestation of cardiac disease. This study aimed to evaluate circulating cardiovascular hormones and hsTnT and their association with mortality in cancer.

Methods We prospectively enrolled 555 consecutive patients with a primary diagnosis of cancer and without prior cardiotoxic anticancer therapy. N-terminal pro BNP (NT-proBNP), mid-regional pro-atrial natriuretic peptide (MR-proANP), mid-regional pro-adrenomedullin (MR-proADM), C-terminal pro-endothelin-1 (CT-proET-1), copeptin, hsTnT, proinflammatory markers interleukin 6 (IL-6) and C reactive protein (CRP), and cytokines serum amyloid A (SAA), haptoglobin and fibrinectin were measured. All-cause mortality was defined as primary endpoint.

Results During a median follow-up of 25 (IQR 16–31) months, 186 (34%) patients died. All cardiovascular hormones and hsTnT levels rose with tumour stage progression. All markers were significant predictors of mortality with HRs per IQR of 1.54 (95% CI 1.24 to 1.90, p<0.001) for NT-proBNP, 1.40 (95% CI 1.10 to 1.79, p<0.01) for MR-proANP, 1.31 (95% CI 1.19 to 1.44, p<0.001) for MR-proADM, 1.21 (95% CI 1.17 to 1.30, p<0.001) for CT-proET-1, 1.22 (95% CI 1.04 to 1.42, p<0.014) for copeptin and 1.21 (95% CI 1.13 to 1.32, p<0.001) for hsTnT, independent of age, gender, tumour entity and stage, and presence of cardiac comorbidities. NT-proBNP, MR-proANP, MR-proADM and hsTnT displayed a significant correlation with IL-6 and CRP.

Conclusions Circulating levels of cardiovascular peptides like NT-proBNP, MR-proANP, MR-proADM, CT-proET-1 and hsTnT were elevated in an unselected population of patients with cancer prior to induction of any cardiotoxic anticancer therapy. The aforementioned markers and copeptin were strongly related to all-cause mortality, suggesting the presence of subclinical functional and morphological myocardial damage directly linked to disease progression.

INTRODUCTION
Cancer is a substantial socioeconomic burden accounting for significant morbidity and mortality in developed countries.1 Malignant cells have been shown to manipulate the endocrine system, controlling hormonal secretion while expressing the appropriate receptors to promote tumour survival and progression.2 Modifying humoral regulation is a main therapeutic modality in the current anticancer therapy for certain types of cancer. Additionally, quantifying plasma hormones has been established in routine clinical practice for tumour diagnosis and surveillance.

In terms of mortality, cancer is only outweighed by cardiovascular disease. The purely mechanistic view of cardiac disease has been extended for the last several decades, and similarly to cancer, now includes a more sophisticated perception focusing on the role of neurohumoral activation and inflammation.3 4 Vasoactive and diuretic hormones are directly related to the severity and, more importantly, to the development and progression of cardiac disease.5 6 The current heart failure therapy is based on the observation that direct modulation of neurohumoral pathways results in a significant reduction of disease progression.

Recent publications reported elevated levels of several emerging cardiovascular neurohormones, which mostly derive from vascular endothelial cells, in patients with cancer.7–11 Malignant cells were shown to produce both vasoactive peptides (adrenomedullin (ADM),7 vasopressin (AVP)8 or endothelin-1 (ET-1)9), as well as cardiac hormones (atrial natriuretic peptide (ANP)10 and B-type natriuretic peptide (BNP)11), yet the physiological role of the latter remains unclear. In most studies, there was no evidence for an underlying morphological cardiac substrate, and the elevated levels of natriuretic peptides have been, therefore, considered as a more sophisticated perception focusing on the role of neurohumoral activation and inflammation.12 13 Lately, elevated levels of troponin T (TnT) have also been detected in cancer,14 15 which have been associated with worse prognosis.16 In contrast to natriuretic hormones, which primarily represent a functional measure, TnT is a specific morphological marker for cardiac cell destruction. Similarly to BNP, increased levels of TnT were also found without evidence of cardiac involvement. However, the association between advanced cancer stages and cancer cachexia potentially accompanied by cardiac wasting is a well-described phenomenon,17 and heart failure...
therapy has been proven successful at improving survival in small animal studies.\(^\text{18}\) This implies that activated cardiovascular neurohormones are less innocent bystanders and equally that TnT should not be overlooked, but rather be viewed as a pathophysiologically relevant marker for estimating the risk of developing systemic cardiovascular disease.

We aimed to investigate the relationship between circulating cardiovascular peptides and mortality in an unselected population suffering from cancer in order to reveal the humoral cross-talk between cancer and cardiac disease.

METHODS

Study population

Between April 2011 and June 2013, we prospectively enrolled consecutive patients with cancer at the Vienna General Hospital, a university-affiliated tertiary care centre. Eligible patients had suspected or confirmed cancer at first presentation, and were excluded if they had received any prior cardiotoxic therapy, showed symptoms of non-stable cardiac disease or clinical signs of infection or if the diagnosis of cancer could not be confirmed in the work-up process. Patients were classified according to tumour entity and tumour stage. Traditional risk factors such as hypertension, diabetes mellitus, smoking status and medical therapy were recorded. Cardiac status was considered to be normal in the absence of cardiac disease, ECG abnormalities and N-terminal pro BNP (NT-proBNP) levels <400 pg/mL. Otherwise, we performed echocardiography to register a cardiac disorder. A significant echocardiographic finding was defined as follows: mildly, moderately or severely reduced LV or RV function, moderate or severe valvular disease or diastolic dysfunction with pseudonormal or restrictive filling patterns. Abnormal cardiac status was then defined as a history of a cardiac disease or an abnormal ECG, regardless of echocardiographic findings or a significant echocardiographic finding in patients with NT-proBNP levels ≥400 pg/mL.

Venous blood samples were obtained at first hospital presentation and analysed on-site, according to our local laboratory standard procedures. In addition to routinely available measurements, including C reactive protein (CRP), haptoglobin, fibrinectin, serum amyloid A (SAA), interleukin 6 (IL-6), hsTnT and NT-proBNP, also levels of mid-regional pro-ANP (MR-proANP), mid-regional pro-ADM (MR-proADM), CT-proET-1 and copeptin—the stable, but inactive fragment of the AVP prohormone—were determined.

Written, informed consent was obtained from all study participants. The study protocol complies with the Declaration of Helsinki, and was approved by the local ethics committee of the Medical University of Vienna (EK 736/2010).

Assays

CRP, haptoglobin, fibrinectin and SAA levels were determined in EDTA and heparinised plasma by means of particle-enhanced immunonephelometry using the BN II System (Siemens Healthcare Diagnostics, Marburg, Germany). Serum IL-6 was detected with a specific ELISA (eBioscience, Vienna, Austria). hsTnT and NT-proBNP measurements were performed in heparin plasma using the Elecsys Systems (Roche Diagnostics, Mannheim, Germany). MR-proANP, MR-proADM, CT-proET-1 and copeptin were measured in EDTA plasma using specific sandwich immunoassays (BRAHMS, Hennigsdorf/Berlin, Germany).

Study endpoint

All-cause mortality was the primary study endpoint, and was obtained from the Central Office of Civil Registration, Austria.

Statistical analysis

Continuous data were presented as median and IQR and categorical data as counts and percentages.

Cox proportional hazard regression analysis was used to evaluate the effect of variables on the overall survival. We adjusted for established risk factors, cardiac status and renal function in a basic model, to account for potential confounding effects. The basic model was built from the variables age, gender, tumour entity (with n >5) and tumour stage, which were included as possible predictors in a stepwise forward Cox regression. The p value for entering the stepwise model was set to 0.05, and the p value for exclusion was set to 0.10. To assess the robustness of the basic model and to test against overfitting, an additional bootstrap procedure was performed, repeating the variable selection for each of a total of 500 samples using the same entering and exclusion criteria. The frequency of a variable entering the model was counted. Significant predictors of the stepwise Cox regression, which entered in more than half of the bootstrap samples, were included. Finally, glomerular filtration rate (GFR) and cardiac status were built in to obtain the basic model. For all Cox regression models, the proportional hazard assumption was assessed and satisfied for all variables based on time interaction tests. For NT-proBNP, MR-proANP and copeptin logarithmic transformations were used in all regression models as they outperformed the untransformed datasets in single predictor models. Results are presented as HRs per IQR. Additionally, Harrell’s concordance index (c-index) was used as a measure of the overall performance of the Cox regression models. The c-index can be interpreted similarly to the well-known area under the curve of the receiver operating characteristics (ROC) curve.

For further analysis of the effects of NT-proBNP, MR-proANP, MR-proADM and hsTnT on mortality, the variables were dichotomised at selected cut-off values (either upper limit of the normal range or median if normal values were not applicable): 125 pg/mL for NT-proBNP, 0.49 nmol/L for MR-proADM, 66.6 pmol/L for CT-proET-1 and 0.005 ng/mL for hsTnT. Time-to-event analysis was performed for the datasets by the means of a log-rank test. The cumulative probabilities of events over time were presented graphically in Kaplan–Meier curves.

Levels of circulating hormones in patients suffering from cancer at different disease stages were compared using the Mann–Whitney U test.

In order to determine the relationships between cytokines and hormones, we performed a multiple linear regression analysis. The variables age, gender and the inflammatory markers CRP, IL-6, haptoglobin, fibrinectin and SAA were used as predictors for each hormone. Moreover, correlation with hsTnT was investigated.

For all tests, two-sided p values <0.05 were considered to indicate statistical significance.

RESULTS

Baseline characteristics

A total of 600 consecutive patients were enrolled in our prospective cohort study. In 45 patients, the diagnosis of cancer could not be confirmed, and they were, therefore, excluded from further analysis. The detailed baseline characteristics of our study population are displayed in table 1. A complete description of tumour entities is presented in table 2.
Table 1 | Baseline characteristics of patients with newly diagnosed cancer (n=555)

<table>
<thead>
<tr>
<th>Patients with cancer (n=555)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years (IQR)</td>
</tr>
<tr>
<td>Male gender, n (%)</td>
</tr>
<tr>
<td>BMI kg/m², (IQR)</td>
</tr>
</tbody>
</table>

**Comorbidities**

- Known CAD, n (%) | 28 (5%) |
- Valvular disease, n (%) | 8 (1%) |
- Heart failure, n (%) | 38 (7%) |
- Stroke/TIA, n (%) | 17 (3%) |
- PAD, n (%) | 19 (3%) |
- Diabetes mellitus, n (%) | 43 (8%) |
- Arterial hypertension, n (%) | 250 (45%) |
- CKD, n (%) | 31 (6%) |
- COPD, n (%) | 113 (20%) |
- Currently smoking, n (%) | 118 (21%) |
- Sinus rhythm, n (%) | 509 (96%) |
- PM or ICD, n (%) | 6 (1%) |

**Medication**

- Beta-blocker, n (%) | 123 (22%) |
- ACE or ARB, n (%) | 166 (31%) |
- Aldosterone antagonist, n (%) | 15 (3%) |
- Digitalis, n (%) | 3 (1%) |
- ASS, n (%) | 111 (20%) |

**Planned therapy**

- 383 (69%) patients received treatment.

**Normal cardiac status, n (%) | 408 (75%)**

**Serum creatinine, mg/dL (IQR) | 0.88 (0.70–1.03)**

**GFR, mL/min/1.73 m² (IQR) | 74.5 (63.7–86.0)**

**hsTnT, ng/mL (IQR) | 0.006 (0.003–0.010)**

**NT-proBNP, pg/mL (IQR) | 128 (64–279)**

**MR-proANP, pmol/L (IQR) | 66.5 (47.2–107.3)**

**MR-proADM, mmol/L (IQR) | 0.56 (0.44–0.72)**

**CT-proET-1, pmol/L (IQR) | 52.5 (40.3–68.1)**

**Copeptin, pmol/L (IQR) | 4.60 (2.90–8.28)**

**CRP, mg/L (IQR) | 0 (0–1)**

**IL-6, pg/mL (IQR) | 2 (2–3)**

**Fibronectin, mg/dL (IQR) | 42 (35–48)**

**Haptoglobin, mg/dL (IQR) | 137 (93–201)**

**SAA, µg/mL (IQR) | 8 (4–26)**

Continuous variables are given as medians and IQR. Counts are given as numbers and percentages.

*Information about planned therapy was collected for all patients excluding those with myeloproliferative neoplasias.

**All, acute lymphoid leukemia; MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; Myelodysplastic malignancies: haematological malignancies with abnormal differentiation of myeloid or lymphoid cell lines (eg, AML, acute myeloid leukemia; ALL, acute lymphoid leukemia; lymphomas, multiple myeloma); Myeloproliferative neoplasias: haematological neoplasias with normal cell differentiation (eg, essential thrombocytosis, polycythaemia vera, myelofibrosis).**

Cox regression analysis

One hundred and eighty-six patients (34%) died during a median follow-up of 25 months (IQR 16–31). The crude and basic adjusted predictive values and the C-statistics for the hormones and hsTnT are displayed in table 3. In the basic model, all included variables except GFR and cardiac status were significant adverse risk factors for mortality, resulting in an overall C-statistic of 0.79.

In the univariate analysis, NT-proBNP, MR-proANP, MR-proADM, CT-proET-1 and copeptin were significant predictors of mortality. After adjustment for the basic model, an independent significant predictive value could be established for all variables. NT-proBNP, MR-proANP and MR-proADM revealed the strongest predictive values (p<0.001 for NT-proBNP and MR-proADM, p<0.01 for MR-proANP). In addition, the cardiac marker hsTnT was similarly associated with mortality. When hsTnT was included in the basic model, the direct association with mortality remained significant for NT-proBNP (p=0.013), MR-proADM (p<0.001), CT-proET-1 (p<0.001) and copeptin (p=0.021), highlighting the independent impact of these hormones in cancer.

Kaplan–Meier analysis confirmed the high discriminatory power of NT-proBNP, MR-proADM, CT-proET-1 and hsTnT with estimated survival rates of 67% and 49% (p<0.001) at a cut-off value of 125 pg/mL for NT-proBNP 71% and 50% (p<0.001) at a cut-off value of 0.49 nmol/L for MR-proADM, 65% and 38% (p<0.001) at a cut-off value of 66.6 pmol/L for CT-proET-1 and 69% and 48% (p<0.001) at a cut-off value of 0.005 ng/mL for hsTnT, respectively, shown in figure 1.
Hormones and hsTnT at different cancer stages

NT-proBNP, MR-proANP, MR-proADM, CT-pro-ET-1, copeptin and hsTnT levels were elevated in patients with cancer, and increased with advancing tumour stage (table 4). IL-6, CRP, haptoglobin and SAA were similarly increased in patients with stage 4 disease compared with less advanced stages (p<0.05 for all).

Correlation between cytokines and hormones/hsTnT

In the multiple linear regression model, direct correlation between the proinflammatory cytokine IL-6 and the inflammatory marker CRP could be shown for MR-proADM (p<0.05 for IL-6 and p<0.001 for CRP) with a corrected R² value of 0.41, NT-proBNP (p<0.05 for IL-6 and p<0.001 for CRP) with a corrected R² value of 0.31 and MR-proANP (p<0.001 for IL-6 and p<0.001 for CRP) with a corrected R² value of 0.31.

Table 3 Unadjusted and adjusted effects on mortality

<table>
<thead>
<tr>
<th>Variables</th>
<th>IQR</th>
<th>Crude HR (95% CI)</th>
<th>p Value</th>
<th>C-statistic</th>
<th>Adj. HR* (95% CI)</th>
<th>p Value</th>
<th>C-statistic</th>
<th>Adj. HR† (95% CI)</th>
<th>p Value</th>
<th>C-statistic</th>
</tr>
</thead>
<tbody>
<tr>
<td>hsTnT, ng/mL</td>
<td>0.007</td>
<td>1.27 (1.20 to 1.34)</td>
<td>&lt;0.001</td>
<td>0.65</td>
<td>1.21 (1.13 to 1.32)</td>
<td>&lt;0.001</td>
<td>0.80</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ln(NT-proBNP), pg/mL</td>
<td>1.465</td>
<td>1.56 (1.34 to 1.83)</td>
<td>&lt;0.001</td>
<td>0.63</td>
<td>1.54 (1.24 to 1.90)</td>
<td>&lt;0.001</td>
<td>0.80</td>
<td>1.33 (1.06 to 1.68)</td>
<td>0.013</td>
<td>0.81</td>
</tr>
<tr>
<td>ln(MR-proANP), pmol/L</td>
<td>0.821</td>
<td>1.45 (1.21 to 1.72)</td>
<td>&lt;0.001</td>
<td>0.59</td>
<td>1.40 (1.10 to 1.79)</td>
<td>0.006</td>
<td>0.80</td>
<td>1.21 (0.94 to 1.55)</td>
<td>0.142</td>
<td>0.81</td>
</tr>
<tr>
<td>MR-proADM, nmol/L</td>
<td>0.280</td>
<td>1.23 (1.20 to 1.36)</td>
<td>&lt;0.001</td>
<td>0.65</td>
<td>1.31 (1.19 to 1.44)</td>
<td>&lt;0.001</td>
<td>0.81</td>
<td>1.24 (1.12 to 1.38)</td>
<td>&lt;0.001</td>
<td>0.81</td>
</tr>
<tr>
<td>CT-proET-1, pmol/L</td>
<td>27.858</td>
<td>1.27 (1.20 to 1.35)</td>
<td>&lt;0.001</td>
<td>0.61</td>
<td>1.21 (1.14 to 1.30)</td>
<td>&lt;0.001</td>
<td>0.80</td>
<td>1.19 (1.11 to 1.28)</td>
<td>&lt;0.001</td>
<td>0.81</td>
</tr>
<tr>
<td>ln(copeptin), pmol/L</td>
<td>1.049</td>
<td>1.49 (1.28 to 1.75)</td>
<td>&lt;0.001</td>
<td>0.60</td>
<td>1.22 (1.04 to 1.42)</td>
<td>0.014</td>
<td>0.79</td>
<td>1.21 (1.03 to 1.42)</td>
<td>0.021</td>
<td>0.80</td>
</tr>
</tbody>
</table>

*HR adjusted to age, tumour stage 4, tumour entity, cardiac status and GFR.
†HR adjusted to age, tumour stage 4, tumour entity, cardiac status, GFR and hsTnT.

Figure 1 Kaplan–Meier estimates of all-cause mortality for (A) N-terminal pro B-type natriuretic peptide (NT-proBNP) with a cut-off value of 125 pg/mL, (B) mid-regional pro-adrenomedullin (MR-proADM) with a cut-off value at 0.49 nmol/L, (C) CT-proET-1 with a cut-off value of 66.6 pmol/L and (D) hsTnT with a cut-off value of 0.005 ng/mL for patients with newly diagnosed tumour disease (p<0.001 between two groups for NT-proBNP, CT-proET-1, MR-proADM and hsTnT, log-rank test).

for both IL-6 and CRP, respectively) with corrected R² value of 0.43. For hsTnT, the association was significant with CRP (p > 0.001), with a corrected R² value of 0.60.

**DISCUSSION**

Elevated levels of cardiovascular peptides and hsTnT have been reported in patients with cancer. However, the underlying mechanism remains speculative since a clinical manifestation of cardiac disease could not be confirmed. To the best of our knowledge, this is the first study to investigate the association between circulating cardiovascular functional peptides (ie, NT-proBNP, MR-proANP, MR-proADM, CT-proET-1 and copeptin) and the cardiac morphological marker hsTnT with all-cause mortality in an unselected population with cancer prior to the induction of anticancer therapy. We demonstrated that these markers are systematically elevated in these patients, up to 100-fold of the upper reference limit, and that they are likewise related to long-term mortality independently of age, gender, tumour entity, tumour stage and manifest cardiac disease at first clinical presentation. Additionally, the hormones NT-proBNP, MR-proANP and MR-proADM significantly correlated with the proinflammatory cytokine IL-6 and the inflammatory marker CRP, as well as with hsTnT as an indicator of myocardial damage.

**Association between cardiovascular peptides, cytokines and cancer**

Alterations to the vasoactive peptides ADM, ET-1 and AVP are involved in the development and progression of cardiac diseases, especially in heart failure. In addition to their role in cardiac disease, ADM, ET-1 and AVP have been implicated in the process of tumour progression through regulation of angiogenesis. Furthermore, natriuretic peptides have been identified as powerful predictors of mortality in various cardiovascular diseases. Although regarded as cardiac hormones, recent data suggest that the biological functions of BNP and ANP are restricted to cardiovascular haemodynamics, and play an important role in cancer by regulating cell growth, alleviating oxidant-induced cell damage, inflammatory processes as well as cancer cachexia.

Current cancer research focuses predominantly on the regulation of the tumour microenvironment by cytokines or ADM, ET-1 and AVP. The effect of ADM on angiogenesis and proliferation has already been proposed as a novel therapeutic target in different cancer types. In analogy, the cytokine hypothesis in heart failure has been established as a complementary concept suggesting that an uncontrolled local activation of cytokines like IL-6 can trigger neurohumoral activation, fibrotic processes and apoptosis. In contrast to cancer, studies have mainly focused on circulating cardiovascular hormones in cardiac disease. However, little is known about the interaction and progression of both diseases when common hormones become systemically active in patients with cancer.

Our data reveal a central role for NT-proBNP, MR-proANP, MR-proADM, CT-proET-1 and copeptin in the prediction of overall survival in patients with cancer. Furthermore, we were able to confirm a significant correlation between the proinflammatory cytokine IL-6 and the inflammatory marker CRP and the hormones NT-proBNP, MR-proANP and MR-proADM. Whether the effect on mortality is primarily due to a detrimental local influence on the tumour microenvironment or is induced by systemic cardiovascular dysregulation cannot be determined.

**Cardiac involvement in cancer**

Occurrence of cardiac disease induced by anticancer treatment is a well-studied clinical situation. However, little is known about cancer-induced cardiac injury independent of anticancer therapy. Associations between increased NT-proBNP and cancer as well as the presence of extremely high peptide levels for specific tumour entities have been previously reported. Nevertheless, these findings could not be correlated with evidence of morphological myocardial dysfunction. Recent studies also demonstrated an association between elevated TnT levels in patients with cancer without evidence of cardiac disease, but an adverse effect on mortality, indicating myocyte cell injury. In accordance with these results, our data show an elevation of all investigated vasoactive peptides and hsTnT as well as a good correlation between the hormones and hsTnT, strengthening this hypothesis. The highly predictive value of cardiovascular peptides may rely on their ability to detect subclinical functional impairment of the cardiovascular system caused by malignant disease prior to detectable changes in routine echocardiographic examinations.

---

**Table 4** Cardiovascular hormones, hsTnT and cytokines at different tumour stages

<table>
<thead>
<tr>
<th>Variables</th>
<th>Stage 1 (n=96)</th>
<th>Stage 2 (n=50)</th>
<th>Stage 3 (n=108)</th>
<th>Stage 4 (n=183)</th>
<th>p Value tumour stages 1, 2, 3 vs tumour stage 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>hsTnT, ng/mL (IQR)</td>
<td>0.005 (0.003 to 0.009)</td>
<td>0.004 (0.003 to 0.007)</td>
<td>0.006 (0.003 to 0.011)</td>
<td>0.007 (0.004 to 0.012)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>NT-proBNP, pg/mL (IQR)</td>
<td>103 (48 to 190)</td>
<td>105 (58 to 191)</td>
<td>118 (73 to 257)</td>
<td>168 (74 to 377)</td>
<td>0.002</td>
</tr>
<tr>
<td>MR-proANP, pmol/L (IQR)</td>
<td>56.2 (45.3 to 83.8)</td>
<td>61.1 (51.4 to 71.2)</td>
<td>59.4 (41.6 to 99.9)</td>
<td>67.7 (47.4 to 113.5)</td>
<td>0.016</td>
</tr>
<tr>
<td>MR-proADM, nmol/L (IQR)</td>
<td>0.49 (0.41 to 0.65)</td>
<td>0.51 (0.44 to 0.63)</td>
<td>0.53 (0.41 to 0.68)</td>
<td>0.62 (0.48 to 0.82)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CT-proET-1, pmol/L (IQR)</td>
<td>45.8 (39.0 to 57.4)</td>
<td>45.8 (38.3 to 58.6)</td>
<td>48.6 (38.0 to 59.1)</td>
<td>57.2 (42.4 to 74.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Copeptin, pmol/L (IQR)</td>
<td>3.7 (2.5 to 6.9)</td>
<td>3.5 (2.5 to 5.0)</td>
<td>3.9 (2.6 to 6.6)</td>
<td>5.4 (3.2 to 10.6)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CRP, mg/L (IQR)</td>
<td>0 (0 to 1)</td>
<td>0 (0 to 1)</td>
<td>0 (0 to 1)</td>
<td>1 (0 to 2)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IL-6, pg/mL (IQR)</td>
<td>2 (2 to 2)</td>
<td>2 (2 to 3)</td>
<td>2 (2 to 3)</td>
<td>2 (2 to 3)</td>
<td>0.011</td>
</tr>
<tr>
<td>Fibronectin, mg/dL (IQR)</td>
<td>43 (36 to 47)</td>
<td>43 (34 to 48)</td>
<td>43 (36 to 49)</td>
<td>42 (35 to 49)</td>
<td>0.504</td>
</tr>
<tr>
<td>Haptoglobin, mg/dL (IQR)</td>
<td>119 (93 to 171)</td>
<td>144 (108 to 214)</td>
<td>146 (96 to 214)</td>
<td>178 (129 to 249)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Serum amyloid, μg/mL (IQR)</td>
<td>7 (4 to 17)</td>
<td>8 (4 to 25)</td>
<td>8 (5 to 19)</td>
<td>17 (6 to 51)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Variables are displayed as median and IQR. Difference between patients with tumour stages 1, 2, 3 versus patients with tumour stage 4 was calculated by the Mann–Whitney U test.

Fonts in bold indicate statistical significance (p < 0.05).

CRP, C reactive protein; CT-proET-1, C-terminal pro endothelin-1; hsTnT, high-sensitive troponin T; IL-6, interleukin 6; MR-proADM, mid-regional pro-adrenomedullin; MR-proANP, mid-regional pro-atrial natriuretic peptide; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
A potential contributor to cardiac impairment in cancer could be cardiac cachexia, which often accompanies advanced cancer states.27, 28 In a rodent hepatoma model, elevated levels of BNP were attributed to cardiac cachexia associated with cardiac remodelling, deterioration of cardiac function and death.18 Interestingly, the treatment of rodents with spironolactone and beta-blocker, targeting established neurohumoral pathways of heart failure, succeeded in reducing mortality,18 but could not yet successfully be translated into clinical practice.

**Clinical implications**

Conventional chemotherapeutics are associated with permanent (type I) or transient (type II) myocardial cell injury, thereby potentially affecting the quality of life and overall survival of patients with cancer.29 Along with other parameters, the measure of cardiac biomarkers such as NT-proBNP, TnT or ultrasensitive cardiac troponin I has been suggested to reflect and help monitor cardiac function during chemotherapy.29, 30 Re-evaluation and cessation of chemotherapy may be considered in patients with increasing levels of the aforementioned biomarkers during cardiotoxic anticancer therapy.29 However, our results indicate that higher initial levels of cardiovascular markers should be expected in patients with cancer. Moreover, elevated NT-proBNP levels, especially in the absence of previous cardiovascular disease, should be interpreted with caution, since an increased NT-proBNP level might reflect a more malignant disease, thereby identifying patients with a more critical need for diagnosis and therapy.

We expect that assessing subclinical myocardial injury detected by hsTnT can provide important additional information to guide cardiotoxic anticancer therapy, indicating cardiac damage prior to reduced LV function becoming apparent in echocardiography. This might be relevant for some therapies classified as type II cardiotoxic substances, which change to type I substances in the presence of pre-existing cardiac disease.29

Furthermore, vasoactive peptides might serve as novel therapeutic targets as recently proposed for ADM.7 In light of our data, more focus should be placed on systemic rather than local effects of vasoactive peptides.

Additionally, small experimental studies have already successfully demonstrated a positive effect of heart failure-specific therapy in patients with cancer.18 Our results provide intellectual support for this approach beyond the prevention of known cardiotoxic drug-related effects.

**Limitations**

One potential limitation of this study is the unsel ective enrolment of patients, including various types of cancer. Neuroendocrine tumours specifically could behave differently, but those only accounts for 2% of our study population, and do not have any influence on our results. Moreover, our data show a comparable predictive value for hsTnT, MR-proADM and CT-proET-1 for solid and myelodysplastic malignancies, but a significant interaction between these groups and MR-proADM as well as CT-proET-1 with regard to the primary outcome (tables 5 and 6). Nevertheless, we intended to investigate peptide activation as a general phenomenon in cancer, without focusing on distinct tumour entities. Further studies might reveal more differences between various types of cancer. Also, laboratory measurements have been performed only at a single time point prior to initiation of systemic anticancer therapy, and studies with serial measurements throughout disease progression might provide additional insights. Finally, while our endpoint is all-cause mortality, precise information about the percentage of

### Table 5  Cardiovascular hormones and hsTnT in myelodysplastic malignancies and solid tumours

<table>
<thead>
<tr>
<th>Variables</th>
<th>Myelodysplastic malignancies (n=68)</th>
<th>Solid tumours (n=388)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Crude HR (95% CI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>hsTnT, ng/mL (IQR)</td>
<td>0.006 (0.003–0.011)</td>
<td>0.006 (0.003–0.011)</td>
<td>0.962</td>
</tr>
<tr>
<td>NT-proBNP, pg/mL (IQR)</td>
<td>153 (59–352)</td>
<td>125 (66–268)</td>
<td>0.520</td>
</tr>
<tr>
<td>MR-proANP, pmol/L (IQR)</td>
<td>69.0 (50.1–117.6)</td>
<td>62.4 (44.4–100.5)</td>
<td>0.306</td>
</tr>
<tr>
<td>MR-proADM, nmol/L (IQR)</td>
<td>0.61 (0.44–0.90)</td>
<td>0.54 (0.43–0.72)</td>
<td>0.129</td>
</tr>
<tr>
<td>CT-proET-1, pmol/L (IQR)</td>
<td>50.1 (39.3–67.6)</td>
<td>50.0 (39.4–66.1)</td>
<td>0.797</td>
</tr>
<tr>
<td>Copeptin, pmol/L (IQR)</td>
<td>4.8 (3.0–9.3)</td>
<td>4.2 (2.7–7.9)</td>
<td>0.226</td>
</tr>
</tbody>
</table>

**Clinical implications**

Conventional chemotherapeutics are associated with permanent (type I) or transient (type II) myocardial cell injury, thereby potentially affecting the quality of life and overall survival of patients with cancer.29 Along with other parameters, the measure of cardiac biomarkers such as NT-proBNP, TnT or ultrasensitive cardiac troponin I has been suggested to reflect and help monitor cardiac function during chemotherapy.29, 30 Re-evaluation and cessation of chemotherapy may be considered in patients with increasing levels of the aforementioned biomarkers during cardiotoxic anticancer therapy.29 However, our results indicate that higher initial levels of cardiovascular markers should be expected in patients with cancer. Moreover, elevated NT-proBNP levels, especially in the absence of previous cardiovascular disease, should be interpreted with caution, since an increased NT-proBNP level might reflect a more malignant disease, thereby identifying patients with a more critical need for diagnosis and therapy.

We expect that assessing subclinical myocardial injury detected by hsTnT can provide important additional information to guide cardiotoxic anticancer therapy, indicating cardiac damage prior to reduced LV function becoming apparent in

### Table 6  Unadjusted effects on mortality and interaction for myelodysplastic malignancies versus solid tumours

<table>
<thead>
<tr>
<th>Variables</th>
<th>IQR</th>
<th>Myelodysplastic malignancies (n=68)</th>
<th>Solid tumours (n=388)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Crude HR (95% CI)</td>
<td>p Value</td>
<td>Crude HR (95% CI)</td>
<td>p Value</td>
</tr>
<tr>
<td>hsTnT, ng/mL</td>
<td>0.007</td>
<td>1.24 (1.08 to 1.42)</td>
<td>0.001</td>
<td>1.35 (1.25 to 1.44)</td>
</tr>
<tr>
<td>ln(NT-proBNP), pg/mL</td>
<td>1.465</td>
<td>1.58 (0.93 to 2.69)</td>
<td>0.093</td>
<td>1.66 (1.39 to 1.98)</td>
</tr>
<tr>
<td>ln(MR-proANP), pmol/L</td>
<td>0.821</td>
<td>1.27 (0.64 to 2.49)</td>
<td>0.495</td>
<td>1.59 (1.33 to 1.91)</td>
</tr>
<tr>
<td>MR-proADM, nmol/L</td>
<td>0.280</td>
<td>2.10 (1.42 to 3.10)</td>
<td>&lt;0.001</td>
<td>1.24 (1.16 to 1.32)</td>
</tr>
<tr>
<td>CT-proET-1, pmol/L</td>
<td>27.858</td>
<td>1.74 (1.09 to 2.76)</td>
<td>0.020</td>
<td>1.25 (1.18 to 1.33)</td>
</tr>
<tr>
<td>ln(Copeptin), pmol/L</td>
<td>1.049</td>
<td>1.55 (0.73 to 2.39)</td>
<td>0.251</td>
<td>1.57 (1.36 to 1.83)</td>
</tr>
</tbody>
</table>

Cox proportional hazard model of cardiovascular hormones and hsTnT for haematological myelodysplastic and solid tumours and the p value for interaction between the groups are shown. HRs refer to a 1-IQR increase in continuous variables.

Fonts in bold indicate statistical significance (p<0.05).

CT-proET-1, C-terminal pro endothelin-1; hsTnT, high-sensitive troponin T; MR-proADM, mid-regional pro-adrenomedullin; MR-proANP, mid-regional pro-atrial natriuretic peptide; NT-proBNP, N-terminal pro B-type natriuretic peptide.
cardiovascular-related death would certainly be of important clinical interest. Since post-hoc interpretations of certifications of death are not reliable, the development of a cardiac disease during cancer progression should be documented in longitudinal studies in the future.

**CONCLUSION**

In conclusion, cardiovascular functional peptides like NT-proBNP, MR-proANP, MR-proADM, CT-pro-ET-1 and copeptin as well as the cardiac morphological marker hsTnT are systemically elevated in patients with cancer prior to cardiotoxic therapy and in the absence of concurrent infection. All of these markers are strongly related to mortality, implying a direct association with disease progression.

**Key messages**

- Patients with cancer may display elevated levels of B-type natriuretic peptide (BNP) and high-sensitive troponin I (hsTnI) in the absence of any clinical manifestation of cardiac disease.
- This study shows that circulating cardiovascular hormones such as N-terminal pro BNP, mid-regional pro-atrial natriuretic peptide, mid-regional pro-adrenomedullin, C-terminal pro-endothelin-1 and copeptin as well as hsTnI are related to cancer disease progression and severity suggesting the presence of subclinical functional and morphological myocardial damage.
- The results provide intellectual support of heart failure therapy in patients with cancer beyond the current focus on preventing therapy-related cardiotoxic side effects. Furthermore, our study provides insight into the expected levels of cardiovascular hormones in a non-selected population of patients with cancer.

**Acknowledgements** We thank Maysa Sarhan for editing the manuscript and Isabella Brodnjak for her valuable help with data collection.

**Contributors** Conception or design of the work: Martin Hülsmann (MH), Richard Pacher (RP), GS, NP, MR, HG, GGS, Michael Hejna (MH), Hülsmann (MH), Richard Pacher (RP) and NP. Analysis or interpretation of data for the work: Martin Hülsmann (MH), NP, SN, CA and GG. WK, SZ-M, CM, GK, LA, SS, BP, WS, Robert Pirker (RP), JD and CZ. Drafting and critically revising the manuscript: Martin Hülsmann (MH), Richard Pacher (RP), GS, NP, MR, HG, GGS, Michael Hejna (MH), Hülsmann (MH), Richard Pacher (RP) and NP. Contribution to the work: NP, SS, BP, WS, Robert Pirker (RP), JD and CZ. Funding This study was supported by an unrestricted grant of Thermo Fisher. Competing interests None declared.

**Ethics approval** Ethics Committee of The Medical University of Vienna.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**REFERENCES**

High cardiovascular hormone/peptide levels in cancer patients linked to shorter survival

Regardless of disease type and stage of progression or prior treatment that may damage heart tissue

High circulating levels of cardiovascular hormones/peptides in cancer patients are linked to shorter survival, regardless of disease type and stage of progression, reveals research published online in the journal *Heart*.

These chemicals, known as biomarkers, are apparent in the absence of any clinical signs of heart disease or infection, and before the start of anti-cancer treatment, some of which is known to damage heart tissue, say the researchers.

Levels of cardiovascular hormones/peptides have been used to monitor the severity and progression of heart tissue damage as a result of either chemotherapy or radiotherapy. But what has not been clear is whether the cancer itself may affect the levels of these chemicals.

In a bid to try and answer this question, the researchers assessed circulating levels of the cardiovascular hormones NT-proBNP, MR-proANP, MR-proADM, CT-pro-ET and copeptin; a chemical called high sensitive troponin (hsTnT), which regulates heart muscle contractions; and proteins indicative of inflammation, including interleukin 6 (IL6) and C reactive protein (CRP), in 555 people diagnosed with cancer for the first time.

None of the participants had yet undergone any treatment with drugs or radiotherapy that might have damaged their heart tissue. Their progress was then tracked for an average of 25 months.

During the monitoring period, almost a third of the patients (34%; 186) died. Analysis of their blood samples showed that levels of all the hormones measured and hsTnT rose in tandem with disease severity, and in some cases were 100 times higher than would be expected.

All these biomarkers were significantly associated with a heightened risk of death from any cause, which ranged in magnitude from 21% to 54%, and 32% for hsTnT.

These associations were evident, regardless of age, gender, tumour type, stage of disease progression or underlying heart disease.

Furthermore, levels of three of the hormones (NT-proBNP, MR-proANP, MR-proADM) and hsTnT were significantly associated with levels of the inflammatory proteins IL6 and CRP.

The findings suggest that all these biomarkers were indicative of heart tissue damage that was not yet clinically evident, but which was directly linked to the progression of the cancer, say the researchers.

Furthermore, the findings back preliminary research which suggests that heart failure drugs may be beneficial for cancer patients above and beyond helping to curb the potentially damaging side effects of cancer treatment, they add.

In a linked editorial, Alexander Lyon of the NIHR Cardiovascular Biomedical Research Unit, of Imperial College and the Royal Brompton Hospital, London, says that the research raises several interesting questions.
“The first is why are these ‘cardiovascular’ biomarkers elevated at baseline diagnosis in patients with cancer?,” he writes. The hormones indicate how well the heart is functioning while HsTnT indicates damage.

“This could imply that the cancer is able to induce a direct or indirect toxic effect on the heart or vasculature to a degree that is clinically relevant,” he suggests.

“A second issue is what these elevated biomarker levels are predicting…More recently, there is increasing knowledge that in some tumours these biomarkers may drive the malignant and metastatic potential,” he writes.

Conceivably, these chemicals may reflect cancer activity and the capacity for spread to other areas of the body or identify pre-existing disease or patients who might be more susceptible to the toxic effects of some cancer treatment, he adds.

The findings open up the potential for new management strategies integrating cardiology and oncology that might improve survival, he says, concluding: “The key next stage will be to reproduce these findings in a prospectively designed multicentre study with larger numbers.”

Notes for editors:
Research: Cardiovascular biomarkers in patients with cancer and their association with all cause mortality doi 10.1136/heartjnl-2015-307848
Editorial: Disparate worlds drawing closer together: cardiovascular biomarkers predict cancer outcomes in treatment-naïve patients